Literature DB >> 12088918

An audit of the insulin-tolerance test in 255 patients with pituitary disease.

Martin Lange1, Ole L Svendsen, Niels E Skakkebaek, Jørn Müller, Anders Juul, Marianne Schmiegelow, Ulla Feldt-Rasmussen.   

Abstract

OBJECTIVE: The insulin-tolerance test (ITT) is currently considered to be the gold standard for evaluating adults suspected of GH deficiency (GHD). The aim of this study was to determine factors that may influence nadir blood glucose (BG) when using a mean insulin dose of 0.1 IU/kg body weight. Furthermore, we wanted to evaluate the safety and GH-related aspects of the ITT.
DESIGN: ITT was performed in 277 patients, of whom 255 (129 females) were eligible for evaluation.
RESULTS: Multiple regression analysis, including the whole population, showed that the major determining factors for nadir BG were basal BG and body mass index (BMI) (P<0.02). No serious adverse event was recorded. Sixty-three percent of all patients tested had severe GHD with peak GH response to hypoglycaemia below 7.8 mIU/l. The positive predictive value for IGF-I was 0.82 and the negative predictive value was 0.47, using a cut-off value corresponding to -2 s.d. GH peak response to hypoglycaemia decreased with increasing numbers of other pituitary hormone deficiencies.
CONCLUSIONS: When determining the dose of insulin based on weight, factors like pre-test BG and BMI should also be considered. We propose an algorithm stating that the dose of insulin should be 0.1 IU insulin/kg body weight minus 2 IU if pre-test BG is <4.0 mmol/l and minus 2 IU if BMI is <20 kg/m(2) in order to take these factors into account. Our findings furthermore support the concept that the low-dose ITT is a safe test in adults, when performed in experienced hands. It was confirmed that IGF-I is not sufficient when diagnosing GHD in adults, and reliable stimulation tests like ITT are required in the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088918     DOI: 10.1530/eje.0.1470041

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Diffusion-weighted imaging of hyperacute cerebral hypoglycemia.

Authors:  P Schmidt; J Böttcher; A Ragoschke-Schumm; H J Mentzel; G Wolf; U A Müller; W A Kaiser; T E Mayer; A Saemann
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

Review 2.  Is the fear from insulin tolerance test in the evaluation of short stature justified?

Authors:  Aaron Hanukoglu; Regina Weisglass
Journal:  Eur J Pediatr       Date:  2022-04-23       Impact factor: 3.183

Review 3.  Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.

Authors:  Zuleyha Karaca; Ashley Grossman; Fahrettin Kelestimur
Journal:  Rev Endocr Metab Disord       Date:  2021-03-26       Impact factor: 6.514

4.  The Optimized Calculation Method for Insulin Dosage in an Insulin Tolerance Test (ITT): A Randomized Parallel Control Study.

Authors:  Yuwen Zhang; Shouyue Sun; Huiying Jia; Yan Qi; Jie Zhang; Lin Lin; Yuhong Chen; Weiqing Wang; Guang Ning
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-09       Impact factor: 5.555

5.  A Comparison of the Blood Glucose, Growth Hormone, and Cortisol Responses to Two Doses of Insulin (0.15 U/kg vs. 0.10 U/kg) in the Insulin Tolerance Test: A Single-Centre Audit of 174 Cases.

Authors:  Phillip Yeoh; Andrew A Dwyer; Ella Anghel; Pierre M Bouloux; Bernard Khoo; Shern Chew; Florian Wernig; Paul Carroll; Simon J B Aylwin; Stephanie E Baldeweg; William Drake; Jeannie Todd; Lindiwe Mangena; Ashley Grossman
Journal:  Int J Endocrinol       Date:  2022-02-08       Impact factor: 2.803

6.  Hypopituitarism in Traumatic Brain Injury-A Critical Note.

Authors:  Marianne Klose; Ulla Feldt-Rasmussen
Journal:  J Clin Med       Date:  2015-07-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.